News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DNAPrint Pharmaceuticals Completes The Development Of A Third Assay For PT-401



10/16/2006 10:40:27 AM

SARASOTA, FL -- (MARKET WIRE) -- October 16, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that KBI BioPharma, Inc., Good Manufacturing Practices manufacturer of PT-401 for the Company's DNAPrint Pharmaceuticals division, has completed and validated a third analytical method using a specially developed isoelectric focusing (IEF) method to be used on PT-401, the dimeric Erythropoietin fusion protein for treating anemia that is currently in preclinical stage.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES